Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer



Status:Completed
Conditions:Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/30/2018
Start Date:November 1, 2012
End Date:August 8, 2017

Use our guide to learn which trials are right for you!

A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer

This randomized phase II trial studies how well bevacizumab with or without anti-endoglin
monoclonal antibody TRC105 (TRC105) works in treating patients with kidney cancer that has
spread to other parts of the body (metastatic). Monoclonal antibodies, such as bevacizumab
and anti-endoglin monoclonal antibody TRC105, may block tumor growth in different ways by
targeting certain cells.

PRIMARY OBJECTIVES:

I. To compare the progression-free survival at 12 and 24 weeks for bevacizumab alone or in
combination with TRC105 (anti-endoglin monoclonal antibody TRC105).

SECONDARY OBJECTIVES:

I. Toxicity and Response Evaluation Criteria in Solid Tumors (RECIST) response rate for the
combination compared to single agent bevacizumab.

TERTIARY OBJECTIVES:

I. To evaluate tumor tissue expression of endoglin (CD105), transforming growth factor, beta
receptor II (TGFBR2), activin A receptor type II-like 1 (ACVRL1) and transforming growth
factor, beta receptor 1 (TGFBR1) kinase from pre- and post-treatment tissue samples in order
to determine whether CD105 and stem cell activation occurs after exposure to anti-vascular
endothelial growth factor (VEGF) therapy as predicted by laboratory models, and whether
exposure to anti-endoglin monoclonal antibody TRC105 affects these changes.

II. To compare the soluble CD105 levels at baseline and after treatment between the group
receiving bevacizumab alone and the group receiving bevacizumab in combination with
anti-endoglin monoclonal antibody TRC105.

III. To compare TGFBR2 levels at baseline and after treatment between the group receiving
bevacizumab alone and the group receiving bevacizumab in combination with anti-endoglin
monoclonal antibody TRC105.

IV. To evaluate whether circulating tumor cells (CTCs) can be detected in this patient
population using parylene membrane filter technology, and whether changes in CTC counts and
CD105 expression on CTCs during therapy correspond to imaging and clinical response.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15.

ARM II: Patients receive bevacizumab as in Arm I and anti-endoglin monoclonal antibody TRC105
IV over 1-4 hours on days 1, 8, 15, and 22.

In both arms, treatment repeats every 28 days for up to 12 courses in the absence of disease
progression or unacceptable toxicity.

After completion of study therapy, patients are followed up for 4 weeks.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed renal cancer; all
histologic subtypes will be eligible

- Patients must have metastatic disease which is measurable, defined as at least one
lesion that can be accurately measured in at least one dimension (longest diameter to
be recorded for non-nodal lesions and short axis for nodal lesions) to >= 20 mm in the
long axis by chest x-ray, >= 10 mm in the long axis by spiral computed tomography
(CT), magnetic resonance imaging (MRI), calipers, or clinical exam, or >= 15 mm in the
short axis for lymph nodes

- Patients must have received at least 1 prior systemic therapy for renal cancer but no
more than 4 prior therapies; they must have documented intolerance to or progression
despite at least 1 systemic therapy; therapy administered in the adjuvant setting
counts toward the prior systemic therapy total; if adjuvant therapy is the patient's
only prior therapy the disease must have recurred during treatment or within 3 months
of discontinuation

- Allowable prior therapies include VEGF tyrosine kinase inhibitor (TKIs), mammalian
target of rapamycin (mTOR) inhibitors, and cytokine therapy (example: interleukin-2
[IL2])

- At least 2 weeks must have elapsed from the last dose of the prior systemic therapy
for biologics and 4 weeks for chemotherapy (6 weeks for nitrosoureas or mitomycin C);
also note that at least 3 weeks should have elapsed since prior TKI administration

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2

- Life expectancy of greater than 6 months

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin =< institutional upper limits or normal (except for Gilbert's)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2.5 X institutional upper limit of normal (except subjects with liver metastases,
who can have AST/ALT =< 5 x ULN)

- Creatinine glomerular filtration rate (GFR) (calculated or measured) > 50 mL/min

- Hemoglobin >= 9 g/dL

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and for
the duration of study participation; should a woman become pregnant or suspect she is
pregnant while she or her partner is participating in this study, she should inform
her treating physician immediately; men treated or enrolled on this protocol must also
agree to use adequate contraception prior to the study, for the duration of study
participation, and 6 months after completion of TRC105 or bevacizumab administration

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had systemic biologic therapy or radiotherapy within 2 weeks prior
to entering the study or those who have not recovered from adverse events related to
their prior therapy

- Patients who have previously been treated with bevacizumab

- Patients who have previously been treated with TRC105

- Patients who are receiving any other investigational agents

- Known central nervous system (CNS) disease except for treated brain metastasis;
treated brain metastases are defined as having no ongoing requirement for steroids and
no evidence of progression or hemorrhage after treatment for at least 3 months, as
ascertained by clinical examination and brain imaging (MRI or CT) (stable dose of
anticonvulsants are allowed); treatment for brain metastases may include whole brain
radiotherapy (WBRT), radiosurgery (RS; gamma knife, linear accelerator [LINAC], or
equivalent) or a combination as deemed appropriate by the treating physician; patients
with CNS metastases treated by neurosurgical resection or brain biopsy performed
within 3 months prior to day 1 will be excluded

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to TRC105 or bevacizumab

- Patients on full-dose anticoagulation will be excluded; antiplatelet therapy will not
be exclusionary

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, unhealed wound, gastrointestinal fistula, symptomatic congestive heart
failure, unstable angina pectoris, myocardial infarction, cerebrovascular accident

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother wishes to participate in the study

- Patients with a history of bleeding diathesis or inherited coagulopathy are excluded;
in addition, those with a history of deep vein thrombosis (DVT) or pulmonary embolus
within 1 year and still requiring active anticoagulation will be excluded; those with
a more remote history of DVT or pulmonary embolus may be eligible but the risk of
recurrent thrombosis should be considered

- Patients with history of hereditary hemorrhagic telangiectasis (HHT-1 and HHT-2)

- Serious or non-healing wound, ulcer, or bone fracture OR history of abdominal fistula,
gastrointestinal perforation or intra-abdominal abscess within 6 months prior to day 1

- Invasive procedures defined as follows:

- Major surgical procedure, open biopsy or significant traumatic injury within 28
days prior to day 1 therapy

- Anticipation of need for major surgical procedures during the course of the study

- Core biopsy within 7 days prior to day 1 therapy

- Patients with clinically significant cardiovascular disease are excluded:

- Inadequately controlled hypertension (HTN) (systolic blood pressure [SBP] > 160
mmHg and/or diastolic blood pressure [DBP] > 90 mmHg despite antihypertensive
medication)

- History of cerebrovascular accident (CVA) within 6 months

- Myocardial infarction or unstable angina within 6 months

- New York Heart Association grade II or greater congestive heart failure

- Serious and inadequately controlled cardiac arrhythmia

- Significant vascular disease (e.g. aortic aneurysm, history of aortic dissection)

- Clinically significant peripheral vascular disease

- Patients with known hypersensitivity to Chinese hamster ovary cell products or other
recombinant human antibodies

- Patients with psychiatric illness/social situations that would limit compliance with
study requirements will be excluded
We found this trial at
29
sites
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
13001 E. 17th Pl.
Aurora, Colorado 80045
303-724-5000
University of Colorado Cancer Center - Anschutz Cancer Pavilion The University of Colorado Denver |...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Camperdown, New South Wales 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
Denver, Colorado 80210
?
mi
from
Denver, CO
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Evanston, IL
Click here to add this to my saved trials
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
?
mi
from
Glenview, IL
Click here to add this to my saved trials
1 Ingalls Dr
Harvey, Illinois 60426
(708) 333-2300
Ingalls Memorial Hospital As the area's only independent not-for-profit healthcare system, Ingalls has the ability...
?
mi
from
Harvey, IL
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
?
mi
from
Hershey, PA
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
Nashville, Tennessee 37232
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Louis Park, Minnesota 55416
?
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
South Pasadena, California 91030
?
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Tampa, Florida 33612
?
mi
from
Tampa, FL
Click here to add this to my saved trials